Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane

A method for treating breast cancer in an individual, the method comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane and a carrier protein, wherein hormone receptor status of estrogen receptor and/or progesterone receptor is used as a basis for selecting the individual to receive treatment.

A method of identifying an individual suitable for breast cancer treatment, the method comprising determining hormone receptor status of estrogen receptor and/or progesterone receptor, wherein the individual is identified as suitable for breast cancer treatment with nanoparticles comprising a taxane and a carrier protein if hormone receptor status is negative for both estrogen receptor and progesterone receptor.

A method of assessing responsiveness of an individual to a breast cancer therapy, the method comprising determining hormone receptor status of estrogen receptor and/or progesterone receptor, wherein the breast cancer therapy comprises administering a composition comprising nanoparticles comprising a taxane and a carrier protein and wherein

• (a) the individual is likely more responsive to the therapy if the hormone receptor status is negative for both estrogen receptor and progesterone receptor and
• (b) the individual is likely less responsive to the therapy if the hormone receptor status is positive for estrogen receptor and/or progesterone receptor.

A kit comprising:

• (a) an agent for detecting hormone receptor status of estrogen receptor and/or progesterone receptor of a breast cancer patient;
• and
• (b) a composition comprising nanoparticles comprising a taxane and a carrier protein.

A kit comprising:

• (a) an agent for detecting hormone receptor status of estrogen receptor and/or progesterone receptor of a breast cancer patient;
• and
• (b) instructions for assessing likely responsiveness to therapy for treating breast cancer based on hormone receptor status of estrogen receptor and/or progesterone receptor, wherein the therapy comprises administering a composition comprising nanoparticles comprising a taxane and a carrier protein.

(canceled)

(canceled)

(canceled)

25-32. (canceled)